Navigation Links
Archemix Announces Completion of Phase 1 Trial of ARC1779

rial blockage."

"We are developing a pipeline of aptamer therapeutics with a proprietary focus in acute cardiovascular and hematological diseases," commented Errol De Souza, Ph.D., President and Chief Executive Officer, Archemix. "The advancement of ARC1779 into Phase 2 will be a key milestone in the development of our broad product portfolio."

About Aptamers

Aptamers are single-stranded nucleic acids that form well-defined three dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies. Aptamers combine the optimal characteristics of small molecules and antibodies, including high specificity and affinity, chemical stability, low immunogenicity and the ability to target protein-protein interactions. In contrast to monoclonal antibodies, aptamers are chemically synthesized rather than biologically expressed.

About Archemix

Archemix Corp. is a privately-held biopharmaceutical company developing aptamers as a class of directed therapeutics for the prevention and treatment of human disease. The company is leveraging its proprietary drug discovery technology to fuel the growth of its development portfolio, which is primarily focused on acute cardiovascular and hematology diseases and cancer. Archemix's broad product pipeline, being developed both by the company as well as its licensees, includes multiple investigational compounds at various stages of development, several of which are moving into Phase 2 clinical trials. Archemix's lead proprietary product, ARC1779, a selective platelet inhibitor, is anticipated to start a Phase 2a and Phase 1b clinical trial before the end of 2007. Archemix' leadership position in intellectual property, technology and expertise relating to aptamers has enabled it to form numerous collaborations with biotechnology and pharmaceutical collaborators, including Merck Serono, Pfizer Inc., Elan Pharma, Nuvelo, Inc., Antisoma plc., and Regado Biosciences.
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Archemix Announces Completion Phase Trial ARC1779
(Date:8/27/2014)... Fla. , Aug. 27, 2014 By now, ... you,re likely not living on this planet. The awareness campaign ... consciousness and has helped to raise over $88.5 Million (and ... getting involved and some companies are starting to as well. ... Orlando, Florida , who actually works with ...
(Date:8/27/2014)... 2014 Pulse Systems, Inc. , an industry-leading ... Management , and Revenue Cycle Management (RCM) solutions , ... by some RCM vendors, at UBM Medica,s Practice Rx ... September 19-20, 2014.  A presenter at the ... with a new session encouraging practices to "Look before You ...
(Date:8/27/2014)... 2014 An experimental drug designed to help regulate ... treatment for anemia of inflammation, according to results from the ... today in Blood , the Journal of ... Anemia is a condition that occurs when red blood ... When an individual has anemia, the body does not get ...
Breaking Medicine Technology:Acorn Stairlifts Gives a Lift to the ALS Ice Bucket Challenge 2Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 2Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 3Pulse Systems Presents the Truth about Revenue Cycle Management Services at Practice Rx 4Drug Represents First Potential Treatment for Common Anemia 2Drug Represents First Potential Treatment for Common Anemia 3
(Date:8/27/2014)... August 28, 2014 BRIC Laparoscopes Market ... 2020?, provides key market data on the BRIC Laparoscopes ... dollars, volume (in units) and average prices (in US ... Laparoscopes and Flexible Tip Video Laparoscopes), Robotic Surgical Systems ... number of advantages to the patient with laparoscopic surgery ...
(Date:8/27/2014)... August 27, 2014 ANS ... a ground breaking anti-cancer therapy for the treatment of ... to prescribe this new medical therapy and will begin ... starting immediately. , NovoTTF™ Therapy is a portable, non-invasive ... 22 years of age and older. It is a ...
(Date:8/27/2014)... Florida (PRWEB) August 27, 2014 Ticket Down ... tickets at Sun Life Stadium in Miami. The ... soccer team on September 5 at Sun Life Stadium in ... meet in a rematch of the World Cup earlier this ... superstar Neymar to injury. The Brazilian Soccer Federation announced earlier ...
(Date:8/27/2014)... August 27, 2014 Power morcellator lawsuits ... courts on behalf of women who allegedly experienced the ... Liebhard LLP reports. According to court documents, one of ... in the U.S. District Court, Northern District of New ... the use of a power morcellator manufactured Karl Storz ...
(Date:8/27/2014)... NC. SonaCare Medical, LLC, the global ... sales of 15 HIFU devices over the past twelve ... for the company’s ablation technology. , “It is ... achieved over the past year, especially since we are ... our most active sales period,” says Mike Klein, CEO ...
Breaking Medicine News(10 mins):Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 2Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 3Health News:Laparoscopes & Endoscopic Reprocessors Market in BRIC (Brazil, Russia, India & China) to 2020 Report Available at RnRMarketResearch.com 4Health News:Atlantic NeuroSurgical Specialists (ANS) Announces Availability of New Therapy for Brain Cancer 2Health News:Atlantic NeuroSurgical Specialists (ANS) Announces Availability of New Therapy for Brain Cancer 3Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Cuts Ticket Prices on World Cup Rematch of Colombia vs. Brazil at Sun Life Stadium in Miami on Sept. 5th 2Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Cuts Ticket Prices on World Cup Rematch of Colombia vs. Brazil at Sun Life Stadium in Miami on Sept. 5th 3Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Lawsuit Alleges Storz Morcellator Caused Spread of Aggressive Uterine Cancer, Bernstein Liebhard LLP Reports 4Health News:SonaCare Medical Announces Twelve Months Sales Results of Fifteen HIFU Devices 2
... , WASHINGTON, July 22 The ... in the new book, Rethinking Responsibility: Reflections on Sex ... Teen and Unplanned Pregnancy, a nonprofit, nonpartisan organization, the volume includes ... , , , ...
... NEW YORK and SAN FRANCISCO, July 22 WeissComm ... Weiss , who was recently named an "Emerging Power Player" by ... the inaugural CLIO Healthcare Awards . The awards honor creative ... , About the CLIO Healthcare Awards and Entry ...
... HOUSTON, July 22 Service Corporation International (NYSE: SCI ) ... the second quarter 2009 on Wednesday, August 5, 2009, after the market ... Thursday, August 6, 2009. Details of the conference call are as ... Service Corporation International Second Quarter 2009 Earnings Conference Call , ...
... Proteus syndrome is a complex disorder associated with ... and unregulated adipose tissue. The overgrowth seen in ... Patients with Proteus syndrome require repeated treatment for ... period. Aggressive treatment may cause severe functional and ...
... , BINGHAM FARMS, Mich., July 22 ... as the new Director of Strategic Partnerships. Terrisca comes to ... Lives Save Dollars (SLSD) initiative where she served most recently as ... with key regional, state, national and international organizations to advance the ...
... , , , ... Board: ACCP) announced today that Jeffrey B. Davis, President & CEO, ... the LifeTech Capital Group on Thursday, July 30, 2009 at 10:45 am EDT. ... Astoria Boca Beach Club in Boca Raton, Florida. , , ...
Cached Medicine News:Health News:National Leaders Examine Sex and Responsibility in New Book 2Health News:National Leaders Examine Sex and Responsibility in New Book 3Health News:WeissComm Group CEO Jim Weiss Appointed Founding Board Member and Judge of First-Ever CLIO Healthcare Awards 2Health News:WeissComm Group CEO Jim Weiss Appointed Founding Board Member and Judge of First-Ever CLIO Healthcare Awards 3Health News:Service Corporation International Announces Schedule For Its Second Quarter 2009 Earnings Release and Conference Call 2Health News:Terrisca Des Jardins, MHSA, joins my1HIE as Director of Strategic Partnerships 2Health News:Access Pharmaceuticals to Present at Jessup & Lamont 2009 Growth Stock Conference 2
... The RapidCycler is the first instrument engineered ... The instrument's rapid temperature cycling system is ... to samples contained in microcapillary tubes or ... the samples with blasts of high velocity ...
... Excellent performance, small footprint, simple intuitive programming ... Primus 25 the ideal personal cycler in ... flexiblock design and the self-adjusting heated lid ... 13x 0.5ml vessels or a microplate of ...
... Ideal for day-to-day temperature ... of 0.1C ,30% reduction ... Peltier or coolant-based cyclers ... temperature ramping ,Options for ...
... System is a rapid, real-time thermal cycler ... samples. By automating much of the testing ... programmable, it is the fastest, easiest to ... the market. The SmartCycler delivers highly accurate ...
Medicine Products: